logo
Medipharm announces Glass Lewis recommends shareholders vote for all nominees

Medipharm announces Glass Lewis recommends shareholders vote for all nominees

Yahoo14-06-2025
MediPharm Labs (MEDIF) announced that independent proxy voting and corporate governance advisory firm Glass, Lewis & Co. published a report on June 12 recommending that MediPharm shareholders vote the GREEN Proxy or voting instruction form FOR the Company's nominees for the Board of Directors at the upcoming Annual and Special Meeting of Shareholders on June 16. Glass Lewis is the second independent proxy advisory firm to recommend voting for the Company's nominees for the Board, following a similar recommendation issued by Institutional Shareholder Services on May 30.
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MEDIF:
Disclaimer & DisclosureReport an Issue
MediPharm Labs Advocates for Current Strategy Amid Shareholder Vote
MediPharm Labs Wins Court Dismissal, Ensures Fair Shareholder Meeting
Apollo releases investor presentation on plan for Medipharm Labs
MediPharm Labs Sells Hope Facility and Expands EU GMP Cultivation
Medipharm Labs closes sale of Hope facility, plans to expand Napanee capacity
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Samsung reports Mobile Experience / Network revenue KRW 3.1T vs. KRW 2.2T y/y
Samsung reports Mobile Experience / Network revenue KRW 3.1T vs. KRW 2.2T y/y

Business Insider

time2 hours ago

  • Business Insider

Samsung reports Mobile Experience / Network revenue KRW 3.1T vs. KRW 2.2T y/y

In Q2 Mobile Experience, says: Smartphone shipments decreased compared to Q1 when new models released, Grew both revenue and OP YoY by robust sales of S25 series, A series and Tablets Maintained solid double-digit profitability via efficient resource management. For the second half, Samsung (SSNLF) looks to: Focus on flagship sales of foldables/S25 series and emphasize AI on A series as well as reinforce AI for tablet/wearables and launch new form-factor products such as XR/TriFold to expand ecosystem and pursue solid profitability despite uncertainties and BOM cost burden. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Morgan Stanley Keeps Their Buy Rating on Tuas Ltd. (TUA)
Morgan Stanley Keeps Their Buy Rating on Tuas Ltd. (TUA)

Business Insider

time2 hours ago

  • Business Insider

Morgan Stanley Keeps Their Buy Rating on Tuas Ltd. (TUA)

In a report released today, James Bales from Morgan Stanley maintained a Buy rating on Tuas Ltd., with a price target of A$7.00. The company's shares opened today at A$5.13. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Bales is a 2-star analyst with an average return of 0.4% and a 40.96% success rate. Bales covers the Consumer Cyclical sector, focusing on stocks such as Collins Foods , Corporate Travel Management Limited, and Temple & Webster Group Ltd. In addition to Morgan Stanley, Tuas Ltd. also received a Buy from Citi's William Park CPA in a report issued on July 29. However, on July 28, TR | OpenAI – 4o initiated coverage with a Hold rating on Tuas Ltd. (ASX: TUA).

Atlas Arteria (MAQAF) Receives a Hold from Morgan Stanley
Atlas Arteria (MAQAF) Receives a Hold from Morgan Stanley

Business Insider

time2 hours ago

  • Business Insider

Atlas Arteria (MAQAF) Receives a Hold from Morgan Stanley

In a report released today, Robert Koh from Morgan Stanley maintained a Hold rating on Atlas Arteria, with a price target of A$5.26. The company's shares closed last Monday at $3.50. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Koh is a 3-star analyst with an average return of 2.2% and a 52.00% success rate. Koh covers the Energy sector, focusing on stocks such as Origin Energy Limited, Ampol Limited, and Viva Energy Group Ltd.. In addition to Morgan Stanley, Atlas Arteria also received a Hold from Morgans's Nathan Lead in a report issued today. However, on the same day, Citi maintained a Buy rating on Atlas Arteria (Other OTC: MAQAF). Based on Atlas Arteria's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $76.3 million and a net profit of $161.1 million. In comparison, last year the company earned a revenue of $70.5 million and had a net profit of $119.8 million

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store